Frequently Asked Questions
The market is segmented based on , By Type (SPECT Radiopharmaceuticals, PET Radiopharmaceuticals), Application (SPECT Applications, PET Applications), Procedure (Central Nervous System, Endocrine, Skeletal, Gastrointestinal, Genito-urinary, Pulmonary), End User (Hospitals and diagnostic centers, Research Institutes) – Industry Trends and Forecast to 2029.
.
The Global Nuclear Medicine Diagnostics Market size was valued at USD 5.90 USD Billion in 2021.
The Global Nuclear Medicine Diagnostics Market is projected to grow at a CAGR of 10.6% during the forecast period of 2022 to 2029.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
